SEATTLE, April 16, 2021, (MEDGADGET) — Clinical Mass Spectrometry: Innovative Solution for Diverse Medical Applications
Clinical mass spectrometry refers to a qualitative and quantitative analytical tool of complex mixtures in all phases of drug development, including identification of the lead compound, and their conformational details. Various clinical laboratories use automation for the management of large number of samples through, either total automation systems or high level analyzer automation that are offered by clinical mass spectrometers such as Matrix Assisted Laser Desorption/Ionization (MALDI-TOF). These automated platforms helps in effective processing of increasingly large workloads. Therefore, clinical laboratories are among the largest end users of this technique. Moreover, in the recent past, there has been various advancements in technology, which has enabled the ease of measuring and distinguishing separate contributions of molecules such as thyroid hormones and 25-hydroxyl vitamins D2 and D3. Application of translational research in the field of mass spectrometry has resulted in the discovery of blood-based biomarkers, endogenous metabolites, tumor markers, and new disease biomarkers. These advancements are expected to fuel adoption of clinical mass spectrometry devices.
To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/193
Clinical mass spectrometry can analyze a limited range of samples such as biomarkers, proteins or drug molecules at once, even in cases of low concentrations thus, making them a valuable tool for diagnostic medical laboratories. Furthermore, it allows researchers to determine pharmacokinetic profiles of drugs that are administered in microdoses. The technology shift from traditional systems to high-resolution technologies such as the Quadrupole-Time of Flight (Q-TOF) mass spectrometry is expected to grow rapidly due to its benefits of accuracy, improved resolution, and sensitivity for clinical diagnostic applications.
The global clinical mass spectrometry market size is estimated to be valued at US$ 697.2 million in 2019, and is expected to exhibit a CAGR of 5.5% over the forecast period (2019 – 2027).
Global Clinical Mass Spectrometry Market Share (%) Analysis, By Product Type, 2019
Source: Coherent Market Insights Analysis (2019)
Order a copy of Clinical Mass Spectrometry Market Report 2021 @ https://www.coherentmarketinsights.com/insight/buy-now/193
Market Dynamics- Drivers
Growing demand for automation in diagnostic techniques to drive growth of the global clinical mass spectrometry market
Increasing demand for automation in diagnostic techniques is expected to drive growth of the global clinical mass spectrometry market during the forecast period. Mass spectrometry assists to perform various diagnostic analyses and study of functional genomics, metabolomics, and proteomics that facilitate development of a cost-efficient analytic platform for analysis of samples. The automated laboratory systems provide several high-end functionalities such as MassEXTEND primer extension and nano liter dispensing of samples on to the spectroCHIPS, and data analysis using pre-loaded workstations that make the task of the clinicians and testing personnel easy and less tedious. Ease of management, quick results, and less complex functionality of these facilities are associated with low costs. Moreover, enhanced quality assays, simplicity, automation, and data reliability, increased sensitivity, reduced cross-reactivity & non-specific binding, and significantly low downtime are advantages offered by mass spectrometers over conventional immunoassays are expected to propel the global clinical mass spectrometry market over the forecast period.
Technological advancements leading to new product launch is a prominent factor fueling growth of the global clinical mass spectrometry market
Introduction of novel technology includes miniaturization of mass spectrometry instruments and increasing automation of the entire spectrometric unit to reduce human efforts and improve efficiency of the instruments. The fully automated analyzer launched by Thermo Fisher in June 2017, is a step closer to achieve entirely automated systems in the mass spectrometry market that can be customized easily to be compatible with the laboratory information systems.
Market Dynamics- Restraints
Major initial capital investments related to the set up and maintenance of these devices is expected to restrain growth of the global clinical mass spectrometry market over the forecast period. Moreover, it is typically unaffordable for small diagnostic laboratories and clinics, especially in emerging economies. These mass spectrometry methods are labor intensive and require technically skilled professionals. Therefore, major capital investment, lack of skilled labors and unaffordability are expected to hinder the global clinical mass spectrometry market over the forecast period.
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/clinical-mass-spectrometry-market-to-surge-past-us-87-billion-by-2025-due-to-widened-application-area-and-new-technological-advancements-365
Among regions, North America accounted for the largest market share in the global clinical mass spectrometry market in 2016, owing to presence of major key players and strategic collaborations in the region. Furthermore, Europe accounted for the second largest market share in the market. Under the Federation of analytical Chemistry and Spectrometry Societies, American Society for Mass Spectrometry was formed in 1969, with over 7,500 scientists working together to make advancements in the clinical applications of mass spectrometry and allied topics in academic, industrial, and governmental laboratories. This in turn, creates a strong network of research base in North America thus, contributing to swift growth of the clinical mass spectrometry market. Asia Pacific is also expected to grow at a substantial rate due to increased investments in R&D by various players and government bodies along with the introduction of new in-house manufacturing and R&D facilities.
Global Clinical Mass Spectrometry Market Value (US$ Mn) & Y-o-Y Growth (%), 2016-2027
Source: Coherent Market Insights Analysis (2019)
Major companies operating in the global clinical mass spectrometry market are Thermo Fisher Scientific Inc., Danaher, Agilent Technologies, Waters, Shimadzu Corporation, PerkinElmer Inc., Bruker, Kore technology, Bergman Messgerate Entwicklung KG, Mass Spectrometry Instruments (MSI), RGB Photonics, and ABLE Biosciences.
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027